Skip to main content

Table 1 Baseline demographic, obstetric, fertility preservation and treatment characteristics of the study participants (n = 38)

From: Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments

Characteristics

 Mean age [median] (years)

32.9 ± 3.5 [33.0]

 Married/with partner; n (%)

28 (74)

 Childless; n (%)

25 (66)

 Overweight / Obese; n (%)

9 (24)

 Former/current smokers; n (%)

11 (29)

 Fertility preservation; n (%)

 No

9 (24)

 Yes

29 (76)

 Embryo CP

2

 Oocyte CP

25

 Ovarian tissue CP

2

 GnRH agonist

2

Tumour biology; n (%)

 HR-positive

15 (39)

 HER2-positive

5 (13)

 Triple negative

9 (24)

 Triple positive

9 (24)

Type of systemic treatments; n (%)

 CT only

8 (21)

 CT + HT

16 (42)

 CT + TT

5 (13)

 CT + TT + HT

9 (24)

CT type; n (%)

 

 Neoadjuvant

21 (55)

 Adjuvant

17 (45)

Type of CT regimen; n (%)

 Anthracycline-based (FEC/AC/EC) + sequential Paclitaxel/Docetaxel

32 (84)

 Taxane-based

6 (16)

Type of HT; n (%) (n = 25)

 Tamoxifen only

7 (28)

 Tamoxifen + GnRHa

10 (40)

 Aromatase inhibitor only

1 (4)

 Aromatase inhibitor + GnRHa

5 (20)

 GnRHa only

2 (8)

  1. Data are presented as mean ± SD or n
  2. BMI Body Mass Index, CT Chemotherapy, HC Hormonal contraception
  3. HER2 Human Epidermal growth factor Receptor-type 2, HR hormonal receptors
  4. HT hormonal therapy, GnRHa Gonadotropin-Releasing Hormone agonist
  5. TT targeted therapy